Apyx Medical (NasdaqGS:APYX) Conference Call Summary Company Overview - **Company**: Apyx Medical Corporation - **Event Date**: October 14, 2025 - **Key Product**: Apyx One Console, a body contouring system Industry Insights - **Market Context**: The surgical aesthetics market is evolving, particularly due to the rise of GLP-1 therapies for weight loss, leading to increased demand for body contouring solutions among post-weight loss patients [4][6] - **Market Size**: GLP-1 therapies are projected to exceed $100 billion by 2030, with 44% of users spending between $2,000 and $5,000 on aesthetic procedures, a 25% increase in spending [6] - **Patient Demographics**: 63% of GLP-1 users are new to aesthetics post-weight loss, indicating a growing patient population for plastic surgeons [6] Product Launch and Performance - **Product Launch**: Apyx One Console received approval in May 2025 and has undergone a successful soft launch with key surgeons across the U.S. [5][4] - **Sales Update**: Commercial sales began in September 2025, with ongoing sales in Q4 2025. A 510(k) submission for the power-assisted handpiece is expected to receive clearance in Q1 2026 [5][6] - **Technological Advancements**: The Apyx One Console integrates multiple technologies, including ultrasound-assisted liposuction and Renuvion for skin tightening, designed based on feedback from leading plastic surgeons [10][12] Clinical Insights - **Surgical Trends**: There has been a decline in liposuction procedures by 10.7%, while surgical lifts have increased by over 20%, reflecting the need for more complex surgical interventions for patients with lax skin [7][8] - **Patient Concerns**: 72% of GLP-1 users report loose skin as their primary concern, with 57% seeking treatment within six months post-weight loss [9] Feedback and Reception - **Surgeon Feedback**: Surgeons have expressed high satisfaction with the Apyx One Console, describing it as revolutionary and comparing it to luxury vehicles like Ferraris and Lamborghinis [13][14] - **Clinical Efficiency**: The integration of technologies in the Apyx One Console has led to improved surgical efficiency, with reduced procedure times and enhanced patient outcomes [32][51] Future Outlook - **Market Positioning**: Apyx Medical is well-positioned to capture growth in the surgical aesthetics market, particularly among post-weight loss patients seeking body contouring solutions [6][4] - **Anticipated Developments**: The upcoming launch of the power-assisted handpiece is expected to further enhance the capabilities of the Apyx One Console, attracting more surgeons and patients [65][66] Additional Insights - **Patient Experience**: The Apyx One Console aims to simplify the surgical process, reducing the need for multiple devices and improving the overall patient experience [21][22] - **Technological Trust**: Surgeons have shown a willingness to adopt the Apyx One Console based on the company's commitment to evidence-based medicine and the collaborative development process involving top surgeons [66][68] This summary encapsulates the key points discussed during the Apyx Medical conference call, highlighting the company's strategic positioning, product innovations, and the evolving landscape of the surgical aesthetics market.

Core Insights - LifeMD, Inc. has announced a collaboration with Novo Nordisk to provide Ozempic at a reduced price of $499 per month for eligible self-pay patients [1][2] - The integration with NovoCare Pharmacy allows access to all FDA-approved doses of Ozempic through LifeMD's virtual care platform [1][2] - The initiative aims to improve access to GLP-1 therapies for millions of Americans suffering from type 2 diabetes, a condition affecting approximately 36 million people in the U.S. [2][3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [4] - The company utilizes a vertically integrated digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care [4] Collaboration Details - The expanded collaboration with Novo Nordisk includes not only Ozempic but also Wegovy, enhancing LifeMD's ability to deliver competitive self-pay prices for FDA-approved GLP-1 therapies [2][3] - LifeMD's telehealth platform is also integrated with LillyDirect pharmacy to provide access to Zepbound (tirzepatide), further diversifying treatment options for patients [3]

Core Insights - Eli Lilly and Company's stock has shown signs of recovery after a significant decline following its second-quarter results, moving above the 50-day Simple Moving Average, indicating a potential bullish trend [1][2][8] - The stock's recovery is attributed to positive data from the ATTAIN-2 phase III study on orforglipron, which met all primary and key secondary endpoints, alleviating some investor concerns raised by earlier disappointing data from the ATTAIN-1 study [3][4][8] Company Performance - Lilly's stock has increased by 18% since the second-quarter results, reflecting improved investor sentiment [4] - The company's cardiometabolic division is its strongest segment, driven by the success of GLP-1 therapies Mounjaro and Zepbound, which together account for approximately 50% of total revenues [5][6] - Mounjaro and Zepbound have seen rising demand, with production capabilities expected to increase significantly in the second half of 2025 [10][9] Product Pipeline and Growth - Lilly is expanding its obesity treatment pipeline, with several new molecules in clinical development, including orforglipron and retatrutide [14][16] - The company has launched Mounjaro in new international markets and received regulatory approvals for additional indications, which are expected to further boost sales [12][11] - Lilly anticipates revenues between $60.0 billion to $62.0 billion in 2025, representing over 30% year-over-year growth [35] Competitive Landscape - The obesity market is projected to reach $100 billion by 2030, leading to increased competition, particularly from Novo Nordisk and other companies developing GLP-1-based therapies [22][24] - Lilly faces competition from Novo Nordisk's semaglutide products and other emerging candidates from companies like Amgen and Viking Therapeutics [22][23][25] Stock Valuation and Estimates - Lilly's stock is currently trading at a price/earnings ratio of 26.35, higher than the industry average of 14.79, but below its 5-year mean of 34.54 [30][27] - The Zacks Consensus Estimate for 2025 earnings per share has increased from $21.90 to $23.03 over the past 60 days, indicating a positive outlook from analysts [33][34] - Despite competitive pressures and a high valuation, the stock's recent recovery suggests potential for long-term investors [36]

Market Overview - The current investment landscape appears stable but is experiencing underlying chaos due to geopolitical tensions, deglobalization, rising debt levels, and supply chain disruptions [2] - Nominal growth is faster but also more volatile and unpredictable, with companies needing to find internal resilience as external support from low interest rates and inflation diminishes [2] Structural Innovations - Innovations such as AI, blockchain, GLP-1 therapies, and decarbonization are fundamentally reshaping business growth [3] - Traditional business models, particularly in software, are threatened by AI's ability to produce similar outputs at low costs [3] Economic Shifts - The year 2025 is seen as a pivotal point marking the end of the initial phase of significant economic regime shifts, with multiple macroeconomic pillars unwinding simultaneously [5] - The U.S. Treasury is now offering meaningful yields on new debt, leading to an annual interest expense approaching $1 trillion, which presents immediate fiscal challenges [10] Supply Chain and Inflation - Governments are localizing supply chains and building strategic stockpiles, leading to inefficiencies and increased costs in infrastructure and manufacturing [11][12] - A new regime of persistent inflation is anticipated, driven by constrained supply and inelastic demand, affecting affordability for consumers and corporations [13] Corporate Performance - The ClearBridge Value Strategy outperformed its benchmark, with strong contributions from sectors like utilities and communication services, particularly benefiting from AI-related developments [19][20] - The health care sector faced challenges due to regulatory concerns and rising medical costs, impacting major companies like UnitedHealth Group [21] Portfolio Positioning - A shift towards value-oriented investments is noted, with sectors tied to industrial activity and energy production expected to benefit from infrastructure rebuilding [23] - The strategy emphasizes the importance of companies with pricing power and real assets, as traditional safe havens face valuation pressures [23] Outlook - The U.S. economy is currently supported by fiscal expansion, but concerns about sustainability are rising, with tariffs and immigration policies likely to increase inflation and reduce growth [26][27] - Opportunities are identified in real assets like gold and copper, which serve as hedges against inflation and geopolitical risks [27]

Analyst & Investor Day May 22, 2025 New York, New York 1 Welcome to Analyst & Investor Day Pravesh Khandelwal Vice President, Investor Relations 2 2 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results ...